Last reviewed · How we verify
CREXONT ER
CREXONT ER is an extended-release formulation of cephalexin, a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
CREXONT ER is an extended-release formulation of cephalexin, a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections caused by susceptible organisms (respiratory tract infections, skin and soft tissue infections, urinary tract infections).
At a glance
| Generic name | CREXONT ER |
|---|---|
| Also known as | IPX203 |
| Sponsor | Impax Laboratories, LLC |
| Drug class | First-generation cephalosporin antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cephalexin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. The extended-release formulation allows for less frequent dosing while maintaining therapeutic drug levels. This mechanism is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections caused by susceptible organisms (respiratory tract infections, skin and soft tissue infections, urinary tract infections)
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Allergic reactions (rash, urticaria)
- Headache
Key clinical trials
- BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease (PHASE4)
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |